

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Pegaspargase for treating acute lymphoblastic leukaemia [ID863]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Consultees and commentators highlighted the following potential equality issues:
--

- | |
|---|
| <ul style="list-style-type: none">• Acute lymphoblastic leukaemia is an orphan disease.• It is unusual in that it is more common in children aged less than 14 years. As such, any decision not to recommend pegaspargase would disproportionately affect children.• If NICE does not approve pegaspargase, children in the UK with acute lymphoblastic leukaemia will be the only children among developed countries not to have access to the drug. |
|---|

The committee agreed that the increased prevalence in children and young people and the low number of people diagnosed with acute lymphoblastic leukaemia is a feature of the disease. Any recommendation resulting from
--

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of pegaspargase for treating acute lymphoblastic leukaemia [ID863]

this appraisal will apply to all people so age, as defined by the Equalities Act, is not a relevant equalities issues. The committee also agreed that variation in access to treatments between countries does not normally constitute an equality issue under equality legislation, because recommendations made by the technology appraisal committee do not address equality of access.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues have been identified by the committee

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been

described in the final appraisal determination, and, if so, where?
Yes, in the summary table of appraisal committee's key conclusions

Approved by Programme Director (name): ...Meindert Boysen.....

Date: 29/06/2016